Merck’s infliximab biosimilar, sold as Renflexis and approved by the FDA in April of last year, was determined to be the lowest priced infliximab option available to the US Department of Veterans Affairs (VA), and was awarded a national contract. Subsequently, it has become the sole infliximab product available on the VA's National Formulary.
Yesterday, Merck announced that it was pleased with the decision of the US Department of Veterans Affairs (VA) to adopt biosimilar medicines “as a means of increasing biologic medicine options for Veterans.”
Merck’s infliximab biosimilar, sold as Renflexis and approved by the FDA in April of last year, was determined to be the lowest priced infliximab option available to the VA, and was awarded a national contract. Subsequently, it has become the sole infliximab product available on the VA National Formulary.
Click here to read more about implementing biosimilars in health systems.
“VA recognizes the value biosimilars bring to the healthcare system, and the award of this contract is consistent with VA’s goal of providing quality treatment options while optimizing resources in the care of Veterans,” said Michael Valentino, MD, chief consultant for pharmacy benefits management.
Renflexis is indicated to treat Crohn disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in the United States. It has seen far less uptake than its fellow infliximab biosimilar, Inflectra, in the US market since its commercial launch, however.
The formulary update is the latest in good news for Merck’s biosimilar infliximab, as earlier this year, Canadian province British Columbia announced that it will reimburse for Renflexis under its public drug plan.
Like the reference infliximab, Remicade, and another infliximab biosimilar in British Columbia, Inflectra, Renflexis was classified as a Limited Coverage Drug, which means that it will not generally be considered as a first-line therapy.
The announcement followed a previous recommendation from the Canadian Agency for Drugs and Technologies in Health that stated the biosimilar be reimbursed for patients for whom infliximab is the most appropriate treatment option.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.